Jazz Pharmaceuticals plc Research and Development Asset Acquired Other than Through Business Combination, Written-off
Jazz Pharmaceuticals plc (JAZZ) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $77.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-03
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $77.00M, a 91.50% decline year-over-year.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $42.50M.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for the quarter ending 2025-06-30 was $905.40M.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for fiscal 2025 was $947.86M, a 9378.62% increase from fiscal 2024.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for fiscal 2024 was $10.00M, a 47.37% decline from fiscal 2023.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for fiscal 2023 was $19.00M, a 95.72% decline from fiscal 2022.
- Jazz Pharmaceuticals plc research and development asset acquired other than through business combination, written-off for fiscal 2022 was $444.15M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $77.00M 10-Q · filed 2026-08-03 | $77.00M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $42.50M derived: sum of 2 quarters · filed 2026-02-24 | $947.90M derived: sum of 3 quarters · filed 2026-08-03 | $947.86M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $42.50M 10-Q · filed 2025-11-05 | $947.90M derived: sum of 2 quarters · filed 2026-08-03 | $947.86M 10-Q · filed 2025-11-05 | $947.90M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $905.40M 10-Q · filed 2026-08-03 | $905.36M 10-Q · filed 2025-08-06 | $905.40M 10-Q · filed 2026-08-03 | $905.36M 10-Q · filed 2025-08-06 | $905.40M derived: sum of 3 quarters · filed 2026-08-03 | $905.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $10.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $10.00M 10-Q · filed 2025-11-05 | $28.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $10.00M 10-Q · filed 2025-08-06 | $28.00M derived: sum of 3 quarters · filed 2026-02-24 | $28.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $10.00M 10-Q · filed 2025-05-07 | $28.00M derived: sum of 2 quarters · filed 2026-02-24 | $28.00M derived: sum of 3 quarters · filed 2026-02-24 | $28.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.00M derived: sum of 2 quarters · filed 2026-02-24 | $18.00M derived: sum of 3 quarters · filed 2026-02-24 | $19.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $1.00M 10-Q · filed 2024-11-07 | $376.00M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $1.00M 10-Q · filed 2024-08-01 | $376.00M derived: sum of 3 quarters · filed 2025-02-26 | $376.00M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-02 | $376.00M derived: sum of 2 quarters · filed 2025-02-26 | $376.00M derived: sum of 3 quarters · filed 2025-02-26 | $445.15M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $375.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $375.00M derived: sum of 2 quarters · filed 2025-02-26 | $444.15M derived: sum of 3 quarters · filed 2025-02-26 | $444.15M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $69.15M derived: sum of 2 quarters · filed 2023-11-08 | $69.15M 10-Q · filed 2023-11-08 | $69.15M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $69.15M 10-Q · filed 2023-08-09 | $69.15M 10-Q · filed 2023-08-09 | $69.15M derived: sum of 3 quarters · filed 2024-02-28 | $69.15M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $36.00M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | $36.00M derived: sum of 3 quarters · filed 2023-03-01 | $46.00M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-04 | $36.00M derived: sum of 2 quarters · filed 2023-03-01 | $46.00M derived: sum of 3 quarters · filed 2023-03-01 | $49.00M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $46.00M derived: sum of 2 quarters · filed 2023-03-01 | $49.00M derived: sum of 3 quarters · filed 2023-03-01 | $251.25M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $10.00M 10-Q · filed 2021-11-09 | $13.00M derived: sum of 2 quarters · filed 2021-11-09 | $215.25M 10-Q · filed 2021-11-09 | $215.25M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $3.00M 10-Q · filed 2021-08-03 | $205.25M 10-Q · filed 2021-08-03 | $205.25M derived: sum of 3 quarters · filed 2022-03-01 | $257.02M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $202.25M 10-Q · filed 2021-05-04 | $202.25M derived: sum of 2 quarters · filed 2022-03-01 | $254.03M derived: sum of 3 quarters · filed 2022-03-01 | $256.23M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $51.77M derived: sum of 2 quarters · filed 2022-03-01 | $53.98M derived: sum of 3 quarters · filed 2022-03-01 | $109.97M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $51.77M 10-Q · filed 2020-11-02 | $53.98M derived: sum of 2 quarters · filed 2020-11-02 | $109.97M 10-Q · filed 2020-11-02 | $109.97M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-06-30 | $2.20M 10-Q · filed 2020-08-04 | $58.20M 10-Q · filed 2020-08-04 | $58.20M derived: sum of 3 quarters · filed 2021-02-23 | $58.20M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-03-31 | $56.00M 10-Q · filed 2020-05-05 | $56.00M derived: sum of 2 quarters · filed 2021-02-23 | $56.00M derived: sum of 3 quarters · filed 2021-02-23 | $56.00M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $0.00 derived: sum of 2 quarters · filed 2021-02-23 | $0.00 derived: sum of 3 quarters · filed 2021-02-23 | $0.00 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | $8.00M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | $8.00M derived: sum of 3 quarters · filed 2020-02-25 | $83.00M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $8.00M derived: sum of 2 quarters · filed 2020-02-25 | $83.00M derived: sum of 3 quarters · filed 2020-02-25 | $85.00M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $83.00M derived: sum of 2 quarters · filed 2020-02-25 | $85.00M derived: sum of 3 quarters · filed 2020-02-25 | $85.00M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $75.00M 10-Q · filed 2018-11-06 | $77.00M derived: sum of 2 quarters · filed 2018-11-06 | $77.00M 10-Q · filed 2018-11-06 | $77.00M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $2.00M 10-Q · filed 2018-08-07 | $2.00M 10-Q · filed 2018-08-07 | $2.00M derived: sum of 3 quarters · filed 2019-02-26 | $17.00M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-02-26 | $15.00M derived: sum of 3 quarters · filed 2019-02-26 | $15.00M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $15.00M derived: sum of 2 quarters · filed 2019-02-26 | $15.00M derived: sum of 3 quarters · filed 2019-02-26 | $23.75M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $15.00M 10-Q · filed 2017-11-07 | $15.00M derived: sum of 2 quarters · filed 2017-11-07 | $23.75M 10-Q · filed 2017-11-07 | $23.75M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-08 | $8.75M 10-Q · filed 2017-08-08 | $8.75M derived: sum of 3 quarters · filed 2018-02-27 | $8.75M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $8.75M 10-Q · filed 2017-05-09 | $8.75M derived: sum of 2 quarters · filed 2018-02-27 | $8.75M derived: sum of 3 quarters · filed 2018-02-27 | $8.75M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $0.00 derived: sum of 2 quarters · filed 2018-02-27 | $0.00 derived: sum of 3 quarters · filed 2018-02-27 | $0.00 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-08 | $0.00 derived: sum of 2 quarters · filed 2016-11-08 | $0.00 10-Q · filed 2016-11-08 | $600.00K derived: sum of 4 quarters · filed 2016-11-08 | ||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | $600.00K derived: sum of 3 quarters · filed 2016-08-09 | $75.60M derived: sum of 4 quarters · filed 2016-08-09 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | $600.00K derived: sum of 2 quarters · filed 2016-05-10 | $75.60M derived: sum of 3 quarters · filed 2016-05-10 | $75.60M derived: sum of 4 quarters · filed 2016-05-10 | ||
| 2014-12-31 | $600.00K 10-K · filed 2016-02-23 | $75.60M derived: sum of 2 quarters · filed 2016-02-23 | $75.60M derived: sum of 3 quarters · filed 2016-02-23 | $202.63M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $75.00M 10-K · filed 2016-02-23 | $75.00M derived: sum of 2 quarters · filed 2016-02-23 | $202.00M 10-Q · filed 2015-11-09 | $202.00M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-05 | $127.00M 10-Q · filed 2015-08-05 | $127.00M derived: sum of 3 quarters · filed 2016-02-23 | $128.00M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-03-31 | $127.00M 10-K · filed 2016-02-23 | $127.00M derived: sum of 2 quarters · filed 2016-02-23 | $128.00M derived: sum of 3 quarters · filed 2016-02-23 | $128.00M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $1.00M derived: sum of 2 quarters · filed 2016-02-23 | $1.00M derived: sum of 3 quarters · filed 2016-02-23 | $4.99M 10-K · filed 2016-02-23 | ||
| 2013-09-30 | $1.00M 10-K · filed 2015-02-24 | $988.00K 10-Q · filed 2014-11-04 | $1.00M derived: sum of 2 quarters · filed 2015-02-24 | $4.99M 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-05 | $4.00M 10-Q · filed 2014-08-05 | ||||
| 2013-03-31 | $4.00M 10-K · filed 2015-02-24 | |||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |